title: Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study.
abstract: OBJECTIVE
  This reports presents the results of a prospective randomized controlled study of combined locoregional targeted immuno-chemotherapy for treatment of patients with liver metastasis from primary colorectal malignancies.
  
  
  METHODS
  Forty eight patients were randomly assigned into one of two groups. Group A (n = 15) included patients who had post-operatively locoregional chemotherapy and Group B (n = 33) included patients who had combined locoregional immuno-chemotherapy.
  
  
  RESULTS
  Statistical analysis shows a clear superiority in the survival and responses of patients treated with immuno-chemotherapy versus chemotherapy alone. Forty five percent of patients in Group B are alive with a mean survival of 20.3 months, ranging from 13 to 29 months, as opposed to no survivors from Group A and a mean survival of only 9.9 months, ranging from 3.6 to 22.5 months. Additionally, 64% of the immuno-chemotherapy group had a positive response while only 13% of the chemotherapy had such a response.
  
  
  CONCLUSIONS
  Our data supports the value of combined immuno-chemotherapy as a treatment for advanced metastatic liver disease.
authors.affiliation: Department of Surgery Athineon Hospital.
authors.forename: N J
authors.initials: NJ
authors.lastname: Lygidakis
authors.forename: K
authors.initials: K
authors.lastname: Stringaris
authors.forename: K
authors.initials: K
authors.lastname: Kokinis
authors.forename: K
authors.initials: K
authors.lastname: Lyberopoulos
authors.forename: S
authors.initials: S
authors.lastname: Raptis
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D003131:Combined Modality Therapy; D003974:Diatrizoate Meglumine / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D007459:Iodized Oil / Q000008:administration & dosage; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D007376:Interleukin-2; D003974:Diatrizoate Meglumine; D016685:Mitomycin; D007459:Iodized Oil; D002955:Leucovorin; D005472:Fluorouracil